IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 812.00, up by 2.40 points or 0.30% from its previous closing of Rs. 809.60 on the BSE.

The scrip opened at Rs. 807.00 and has touched a high and low of Rs. 814.00 and Rs. 802.00 respectively. So far 8400 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1119.00 on 13-Jan-2021 and a 52 week low of Rs. 720.80 on 23-Aug-2021.

Last one week high and low of the scrip stood at Rs. 815.70 and Rs. 793.20 respectively. The current market cap of the company is Rs. 15823.33 crore.

The promoters holding in the company stood at 69.48%, while Institutions and Non-Institutions held 16.94% and 13.58% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Doryx Tablets, 75 mg, 100 mg, 150 mg, and 200 mg, of Mayne Pharma International Pty (Mayne).

Doxycycline Hyclate Delayed-Release Tablets are indicated' to reduce the development of drug resistant bacteria and maintain the effectiveness of Doxycycline Hyclate Delayed Release Tablets and other antibacterial drugs, Doxycycline Hyclate Delayed Release Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

The company has received year to date (YTD) 16 approvals (12 final approvals and 4 tentative approvals) and a cumulative total of 155 ANDA approvals (135 final approvals and 20 tentative approvals) from USFDA.